Graft-versus-host disease (GVHD) continues to be a leading cause of morbidity and mortality
after allogeneic hematopoietic stem cell transplantation. Recent insights into intestinal�…

Superb biological effectiveness and dose conformity represent a rationale for heavy-ion
therapy, which has thus far achieved good cancer controllability while sparing critical normal�…

Salivary glands are essential organs that produce and secrete saliva to the oral cavity.
During gland morphogenesis, many developmental processes involve a series of�…

Alloantigen expression on host antigen-presenting cells (APCs) is essential to initiate graft-
versus-host disease (GvHD); therefore, alloantigen expression on host target epithelium is�…

Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an
ultimate therapeutic target for AML. Here we identified T cell immunoglobulin mucin-3 (TIM�…

Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow
transplantation (BMT), and damage to the gastrointestinal (GI) tract plays a critical role in�…

Background In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an
autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall�…

Alloantigen expression on host APCs is essential to initiate graft-vs-host disease (GVHD);
however, critical APC subset remains to be elucidated. We compared the ability of dendritic�…

Background Chronic graft-versus-host disease (GVHD), a major complication of allogeneic
stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in�…

Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell�…